Bayer HealthCare reports positive trial data for Xarelto

Pharmaceutical Company Product News

Bayer HealthCare has reported positive data from a new phase III clinical study of Xarelto, in which the drug met its primary endpoint.

The rivaroxaban therapy has been trialled among Japanese patients in a study called J-Rocket AF, which was conducted among patients with non-valvular atrial fibrillation at risk of stroke, in order to evaluate its safety.

When compared to warfarin, it was shown to offer non-inferior performance when assessing composite criteria of major and non-major clinically relevant bleeding.

Dr Masatsugu Hori, steering committee chairman for the latest trial, said: "It is important that rivaroxaban demonstrated non-inferior safety and that there were numerically fewer intracranial haemorrhages versus warfarin."

Thus far, Xarelto has been approved in more than 85 different countries as a means of preventing venous thromboembolism events among adult patients following elective hip or knee replacement surgery.

Earlier this month, Bayer HealthCare announced a new research alliance with the Ludwig Boltzmann Institute for Lung Vascular Research, which will focus on studies into pulmonary hypertension.

See all the latest jobs in Pharmaceutical
Return to news

Tags